IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BELLUCCI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.291
EU - Europa 3.490
AS - Asia 1.192
OC - Oceania 12
SA - Sud America 12
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.269
PL - Polonia 1.592
CN - Cina 716
UA - Ucraina 556
IT - Italia 434
DE - Germania 320
FI - Finlandia 175
HK - Hong Kong 171
SG - Singapore 120
GB - Regno Unito 110
IE - Irlanda 107
FR - Francia 98
IN - India 74
VN - Vietnam 66
BE - Belgio 24
CA - Canada 22
CZ - Repubblica Ceca 21
SE - Svezia 21
TR - Turchia 14
AU - Australia 11
KR - Corea 9
BR - Brasile 7
RU - Federazione Russa 7
IR - Iran 6
NL - Olanda 6
ES - Italia 5
EU - Europa 5
IL - Israele 4
EG - Egitto 3
GR - Grecia 3
JP - Giappone 3
MU - Mauritius 3
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
EE - Estonia 2
JO - Giordania 2
LB - Libano 2
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
DK - Danimarca 1
GE - Georgia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TN - Tunisia 1
Totale 9.010
Salva come PNG Salva come JPEG
Città #
Warsaw 1.592
Fairfield 561
Woodbridge 427
Jacksonville 421
Chandler 292
Ashburn 285
Dearborn 270
Cambridge 245
Houston 240
Seattle 213
Ann Arbor 207
Wilmington 199
Brescia 195
Princeton 192
Hong Kong 170
Nanjing 142
Beijing 123
Helsinki 113
Dublin 106
New York 97
Singapore 71
Dong Ket 66
Des Moines 50
Jinan 48
Nanchang 47
Milan 42
Changsha 40
Hebei 40
Shenyang 38
Pune 36
Munich 34
Shanghai 33
Boardman 31
San Diego 30
Tianjin 27
Brussels 23
Kunming 23
Brno 18
Ningbo 17
Jiaxing 16
Taizhou 16
Toronto 15
London 14
San Francisco 14
Los Angeles 13
San Giuliano Milanese 13
Lappeenranta 12
Zhengzhou 12
Hangzhou 11
Hefei 11
Lanzhou 11
Rome 11
Guangzhou 10
Lancaster 10
Verona 10
Romola 9
San Donà Di Piave 9
Kocaeli 8
Taiyuan 8
Cattolica 7
Fuzhou 6
Orange 6
Pavia 6
Ardabil 5
Canberra 5
Haikou 5
Kilburn 5
Napoli 5
Oxford 5
Phoenix 5
San Cesareo 5
San Mateo 5
Augusta 4
Changchun 4
Fulda 4
Melbourne 4
Norwalk 4
Padova 4
Providence 4
Redmond 4
Bergamo 3
Bologna 3
Cairo 3
Chions 3
Kafr Manda 3
Leawood 3
Monmouth Junction 3
Olomouc 3
Ottawa 3
Paris 3
São Paulo 3
Ulsan 3
Xian 3
Amman 2
Campo San Martino 2
Chicago 2
Cornate d'Adda 2
Desio 2
Florence 2
Fremont 2
Totale 7.192
Salva come PNG Salva come JPEG
Nome #
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation 271
Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease 250
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 248
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 247
The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging 227
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases 225
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 220
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. 215
Mild inflammatory profile without gliosis in the c-rel deficient mouse modeling a late-onset parkinsonism 211
INDUCTION OF INFLAMMATORY MEDIATORS AND MICROGLIAL ACTIVATION IN MICE TRANSGENIC FOR MUTANT P301S TAU PROTEIN 205
Living in promiscuity: The multiple partners of alpha-synuclein at the synapse in physiology and pathology 177
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 170
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 157
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 153
c-Rel deficient mice, a mouse model of "spreading" PD-like pathology. 142
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 142
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure 139
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 136
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases 135
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 123
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 121
DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SIGNALLING PATHWAYS IN THE HIPPOCAMPUS OF CRND8 TRANSGENIC MOUSE, A MODEL OF ALZHEIMER'S DISEASE 118
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 116
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation 115
The proximity ligation assay: an high throughput technique for protein analysis in neuroscience 114
From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease 110
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 109
Synapsin III alterations in Parkinson's disease 108
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. 106
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 106
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 105
Mitochondrial Dysfunction and Alpha-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First? 104
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons 103
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology 103
EFFECT OF SUBCHRONIC ADMINISTRATION OF METRIFONATE, RIVASTIGMINE AND DONEPEZIL ON BRAIN ACETYLCHOLINE IN AGED F344 RATS 96
CHOLINERGIC DYSFUNCTION, NEURONAL DAMAGE AND AXONAL LOSS IN TGCRND8 MICE 95
COMBINED TREATMENT WITH ATORVASTATIN AND MINOCYCLINE SUPPRESSES SEVERITY OF EAE 94
ABNORMAL PROCESSING OF TAU IN THE BRAIN OF AGED TGCRND8 MICE 92
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 92
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. 88
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 88
ALPHA-SYNUCLEIN MODULATES SYNAPSIN III IN NIGROSTRIATAL DOPAMINERGIC NEURONS: IMPLICATIONS FOR PARKINSON'S DISEASE 80
Parkinson's disease: from synaptic loss to connectome dysfunction 76
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 76
Study of alpha-synuclein fibrillation: State of the art and expectations 76
PGRN gene silencing in primary neuronal cultures: a model of FTLD-U 75
Alpha-synuclein modulates the localization, expression and function of NR2B-containing NMDA receptors: implications in the pathogenesis of Parkinson's disease 74
BETA-AMYLOID INFLAMMATION AND CHOLINERGIC HYPOFUNCTION IN THE RAT BRAIN IN VIVO: INVOLVEMENT OF P38MAPK PATHWAY 72
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 71
Synapsin III Alteration in Parkinson's disease 71
Synapsin III Alteration in Parkinson's disease 70
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 69
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 69
Selective dopaminergic alpha-synuclein pathological changes following glucose deprivation "in vitro": implications for Parkinson's disease 67
NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease 67
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease 66
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 66
The good and bad of therapeutic strategies that directly target α-synuclein 66
Alpha-synuclein aggregation in dopaminergic cells is modulated by glucose metabolism 65
Effects of rofecoxib treatment on brain inflammatory reaction and cholinergic function in beta-(1-42) injected rats into the nucleus basalis 65
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 65
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 65
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 65
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 63
Alpha-synuclein and NMDA receptors: a novel postsynaptic couple playing a pivotal role in the regulation of the functional activity of nigral dopaminergic neurons 61
In vivo effects of NSAIDs on amyloid beta(1-42)-induced brain neurotoxicity 60
Novel perspectives for Parkinson’s disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets 60
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. 57
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease 57
Non-steroid antiinflammatory agents (nsaids): are they a valid approach to Alzheimer’s disease prevention? 56
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 56
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 56
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 55
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease 54
Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy 54
Ex vivo characterization of progranulin gene silencing in primary neuronal cultures to study the biological basis of FTLD-U 54
Effects of novel NSAIDs on brain inflammation and release of neurotrasmitters in animal models of neurodegeneration 53
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia 53
EXPERIMENTAL BRAIN INFLAMMATION AND NEURODEGENERATION AS MODEL OF ALZHEIMER'S DISEASE: PROTECTIVE EFFECTS OF SELECTIVE COX-2 INHIBITORS 52
Induction of the Unfolded Protein Response by alpha-synuclein in experimental models of Parkinson's disease 52
NSAIDs in animal models of Alzheimer's disease 52
Neuroprotective effects of D2/D3 agonists in an "in vitro" model of dopaminergic degeneration 51
NSAIDs in animal models of Alzheimer’s Disease 51
NSAIDs in Animal Models of Alzheimer's disease 49
THE SELECTIVE CYCLOOXIGENASE-2 INHIBITOR ROFECOXIB SUPPRESSES BRAIN INFLAMMATION AND PROTECTS CHOLINERGIC NEURONS FROM EXCITOTOXIC DEGENERATION IN VIVO 48
Nuovi Aspetti di Fisiopatologia del DLB e PDD 47
Alpha-synuclein absence affected mitochondrial fusion and functions 47
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 47
MicroRNA‑34a‑5p expression in the plasma and its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study 46
COMPARISON BETEWEEN FLURBIPROFEN AND ITS NITRIC OXIDE-RELEASING DERIVATIVES HCT-1026 AND NCX-2216 ON ABETA(1-42)-INDUCED BRAIN INFLAMMATION AND NEURONAL DAMAGE IN THE RAT 44
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 44
ANALOGHI STRUTTURALI DEL METILFENIDATO COME AGENTI DISEASE-MODIFYING DELLA MALATTIA DI PARKINSON 39
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 38
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 33
The association between α-synuclein and α-tubulin in brain synapses 29
NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients 28
Validation of synapsin III as a therapeutic target for Parkinson’s disease in the AAV-mediated alpha-synuclein mouse model 28
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype 27
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 27
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 20
Totale 9.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.193 0 0 0 199 166 413 291 308 191 368 123 134
2020/20211.651 67 165 65 182 102 160 53 195 194 193 162 113
2021/2022810 49 153 31 32 9 46 33 62 34 80 92 189
2022/2023866 125 10 30 63 90 212 7 99 132 21 39 38
2023/2024967 63 20 91 60 57 177 46 50 185 20 32 166
2024/202588 15 36 35 2 0 0 0 0 0 0 0 0
Totale 9.369